Company Overview and News

37
Deutsche Bank to pay US$205 million to settle NY currency rigging charges

40m channelnewsasia
Deutsche Bank AG has agreed to pay a fine of US$205 million for violations of New York's banking laws, the state's department of financial Services said on Wednesday.
STAN DB BNPQY MS.PRE SCGLY MS.PRF MS.PRG BNPQF MS.PRA BNPZY SCGLF MS.PRI STAB MS.PRK 580001 STAC SCBFF STAN 2888 GLE MS

37
Deutsche Bank to pay $205 mln to settle NY currency rigging charges

1h reuters
June 20 (Reuters) - Deutsche Bank AG has agreed to pay a fine of $205 million for violations of New York’s banking laws, the state’s department of financial Services said on Wednesday.
STAN DB BNPQY MS.PRE SCGLY MS.PRF MS.PRG BNPQF MS.PRA BNPZY SCGLF MS.PRI STAB MS.PRK 580001 STAC SCBFF STAN 2888 GLE MS

37
Deutsche Bank to pay $205 million to settle NY currency rigging charges

1h reuters
(Reuters) - Deutsche Bank AG (DBKGn.DE) has agreed to pay a fine of $205 million for violations of New York’s banking laws, the state’s department of financial Services said on Wednesday.
STAN DB BNPQY MS.PRE SCGLY MS.PRF MS.PRG BNPQF MS.PRA BNPZY SCGLF MS.PRI STAB MS.PRK 580001 STAC SCBFF STAN 2888 GLE MS

9
EU mergers and takeovers (June 20)

2h reuters
BRUSSELS, June 20 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
39IB ABFOF LGEPF DIREN BNPQY LYB HOGGF BNPQF DTEGF ICP BNPZY LGEAF PAY PWOPY GPN TOT LALWF ABRTY LGLD HRG LGEJY DTEGY LGEIY

6
Oil steady ahead of Opec meeting

3h malaymail
LONDON, June 20 — Oil prices steadied today, supported by a drop in US commercial crude inventories and the loss of storage capacity in Libya, but under pressure ahead of a meeting of Opec exporters which may increase global production.
BNPZY BNPQY BNPQF

238
SoftBank's Son remakes his inner circle with three newcomers

12h theedgemarkets
TOKYO (June 20): Masayoshi Son is elevating two SoftBank Group Corp executives and one outsider to his inner circle, appointments that become official on Wednesday.
DB BNPQY GS.PRB GS.PRA SFTBF FIG GS GLSSP AAPL JEF SFTBY JBK TMUSP GSC GS.PRICL TMUS TFG BNPQF GSJ GS.PRJ BNPZY GS.PRI S GS.PRD GS.PRC 9984 GJS GS.PRN GS.PRK

6
Amplify Energy Announces Additions to its Leadership Team

20h globenewswire
HOUSTON, June 19, 2018 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (“Amplify” or the “Company”) (OTCQX:AMPY) announced today that Polly Schott joined the Company as Chief Administrative Officer. In this role she will collaborate with Ken Mariani as President and CEO, the Board and the management team to define and execute the Company’s strategic objectives in order to reach its full economic potential with alignment from employees to shareholders.
BNPZY AMPY BNPQY BNPQF

9
EU mergers and takeovers (June 19)

21h reuters
BRUSSELS, June 19 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
39IB ABFOF DIREN BNPQY SMFG HOGGF DTEGF SMFNF LGEAF LGEIY LGEPF LYB BNPQF ICP BNPZY PAY PWOPY 8316 GPN TOT LALWF ABRTY SSUMF LGLD HRG LGEJY DTEGY

358
Banks to Raise Payouts Ignoring Tougher Stress Test

2018-06-19 zacks
The Fed will be announcing the results of bank stress tests on Jun 21 and results of its Comprehensive Capital Analysis Review ("CCAR") on Jun 28. The tests, which are an annual affair and a must for banks since the 2008 financial meltdown, are designed to ensure that they are in a healthy position to handle crisis during an economic downturn. Looking back, President Donald Trump in May signed the biggest rollback of bank regulations since the global economic downturn into law.
C.WSA BNPQY GS.PRB GS.PRA 83SF GLSSP DBXFF 83SK STI-A UBS.PRDCL MS DBFBF STI.WS.B STI.WS.A CSSLF DBAGF GS.PRJ GS.PRI BNPZY GS.PRD GS.PRC DBZQF GS.PRN DBTMF GS.PRK BCS.PRD DB BCS.PRC DGLD BCS.PRA WFC.PRL WFC.PRJ CS BAC WFC.PRT C.WS.B WFC.PRR DBCBW WFC.PRQ WFC.PRP WFC.PRO C.WS.A WFC.PRN C.PRP DBQFF C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV 47MC C.PRS RY C.PRL VIIX GSC GS.PRICL C.PRJ VIIZ C.PRK BNPQF C.PRG DBZFF GSJ C.PRC CSGKF C.PRPCL TVIX GJS ULSGF DBWQF XIV DBFFF BCS MS.PRE MS.PRF MS.PRG MS.PRA UGLD DBCQF BBT JBK BAC DSLV TFG DBFMF DBWGF RY STI MS.PRI MS.PRK CGBBW WFCNP DBQZF DBWFF GS UBS STI.PRE WFC WFC.WS C BCS.PR DBYQF ZIV USLV

6
MOVES-BNP Paribas Asset Management names co-head of Distribution Europe

2018-06-19 reuters
June 19 (Reuters) - The investment management arm of BNP Paribas SA on Tuesday said it had named Fabien Madar as co-head of Distribution Europe, within BNP Paribas Asset Management’s global client group.
BNPZY BNPQY BNPQF

6
Hong Kong poised to create Chinese treasury bond futures market

2018-06-18 scmp
Hong Kong Exchanges and Clearing (HKEX) is expected to relaunch an improved version of Chinese treasury bond futures in Hong Kong, possibly as soon as this year, in an effort to broaden the yuan-denominated financial market and deepen the trading liquidity of the Bond Connect scheme.
BNPZY BNPQY BNPQF

22
IPOs This Week: 6/18/18

2018-06-18 seekingalpha
After last week's news of AT&T's approval to buy out Time Warner and the acquisition of Adaptive Insights by Workday, I will discuss the acquisition environment for IPOs.
BNPZY T BNPQY TWX BNPQF TWC

25
Central Bankers Will Debate Policy, and OPEC Meets on Output - The New York Times

2018-06-18 nytimes
The Senate will also vote on an amendment that would block President Trump’s ZTE deal, and the Fox board will weigh Comcast’s $65 billion offer.
BNPZY DB BNPQY NYTAB BNPQF DIS

19
First Hawaiian Bank: Attractive Banking Franchise Poised To Benefit From Rising Rates

2018-06-18 seekingalpha
First Hawaiian Bank has a very strong franchise in the markets it focuses on - unlike most banks it actually has pricing power.
BNPZY FHB BNPQY BOH BNPQF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: F1058Q238